CN Patent
CN105486785A — 阿普斯特中对映异构体杂质的检测方法
Assigned to Chengdu Baiyu Jingelai Pharmaceutical Co Ltd · Expires 2016-04-13 · 10y expired
What this patent protects
本发明公开了一种阿普斯特中对映异构体(Ⅰ)的检测方法。该方法采用的是蛋白质型手性色谱柱,在克服了现有淀粉涂覆型手性柱的寿命较短缺点的同时,有效将阿普斯特中对映异构体分离检测出来,检测结果准确、可靠,并且具有线性关系优异、精密度高、稳定性好、重复性好、回收率好、操作简便、成本低等诸多优点,适合于推广应用。
USPTO Abstract
本发明公开了一种阿普斯特中对映异构体(Ⅰ)的检测方法。该方法采用的是蛋白质型手性色谱柱,在克服了现有淀粉涂覆型手性柱的寿命较短缺点的同时,有效将阿普斯特中对映异构体分离检测出来,检测结果准确、可靠,并且具有线性关系优异、精密度高、稳定性好、重复性好、回收率好、操作简便、成本低等诸多优点,适合于推广应用。
Drugs covered by this patent
- Otezla (APREMILAST) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.